Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELINDA: Tisagenlecleucel vs Standard of Care in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma
jRCT1080224814Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 3, randomised, open-label trial in aggressive B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 2 more comparing Tisagenlecleucel arm with Standard-of-care salvage therapy arm (2 arms). Started Jul 2019; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
aggressive B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)primary mediastinal large B-cell lymphoma (PMBCL)large-cell lymphoma
Beyond the preview
Go deeper on jRCT1080224814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224814.